{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:47:51Z","timestamp":1788814071347,"version":"build-2803163510"},"reference-count":22,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Studies on chronic myeloid leukemia (CML) in the Gulf region are scarce, consisting of a survey and expert meeting that included 15 experts in 2023 which discussed CML diagnosis, testing, treatment objectives, toxicities, and discontinuation in the Gulf region. Most patients were reported to be in first-line therapy, and the most common treatments were imatinib\/imatinib generic in first-line and dasatinib in second- and third-lines. Mutation analysis was not reported to be routinely performed at the time of diagnosis but rather in case of progression to accelerated\/blast phase or any sign of loss of response. While all participants were aware that BCR-ABL should be monitored every three months during the first year of treatment, 10% reported monitoring BCR-ABL every six months in practice due to test cost and lab capability. The most important first-line therapy objective was \u201cachievement of major molecular response\u201d (MMR) in younger patients and \u201coverall survival\u201d in older ones. The most important treatment objectives were \u201cMMR\u201d and \u201cearly molecular response followed by prolongation of overall survival\u201d in the short term and \u201ctreatment-free remission\u201d in the long term. The current practices in CML in the Gulf region appear to be similar to global figures.<\/jats:p>","DOI":"10.3390\/cancers16112114","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T11:43:48Z","timestamp":1717155828000},"page":"2114","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Current Status and Management of Chronic Myeloid Leukemia in the Gulf Region: Survey Results and Expert Opinion"],"prefix":"10.3390","volume":"16","author":[{"given":"Giuseppe","family":"Saglio","sequence":"first","affiliation":[{"name":"Department of Hematology, University of Turin, 10124 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Yassin","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation, Doha P.O. Box 3050, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4669-0233","authenticated-orcid":false,"given":"Ahmad","family":"Alhuraiji","sequence":"additional","affiliation":[{"name":"Kuwait Cancer Control Center, Shuwaikh 1031, Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar","family":"Lal","sequence":"additional","affiliation":[{"name":"Tawam Hospital, Al Ain P.O. Box 5674, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arif","family":"Alam","sequence":"additional","affiliation":[{"name":"Tawam Hospital, Al Ain P.O. Box 5674, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faraz","family":"Khan","sequence":"additional","affiliation":[{"name":"American Hospital, Dubai P.O. Box 3050, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Khadada","sequence":"additional","affiliation":[{"name":"Kuwait Cancer Control Center, Shuwaikh 1031, Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Osman","sequence":"additional","affiliation":[{"name":"Tawam Hospital, Al Ain P.O. Box 5674, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Islam","family":"Elkonaissi","sequence":"additional","affiliation":[{"name":"Shaikh Shakhbout Medical City, Abu Dhabi P.O. Box 11001, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Marashi","sequence":"additional","affiliation":[{"name":"Dubai Hospital, Dubai P.O. Box 7272, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abuhaleeqa","sequence":"additional","affiliation":[{"name":"Yas Clinic, Abu Dhabi P.O. Box 44852, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2937-8838","authenticated-orcid":false,"given":"Murtadha","family":"Al-Khabori","sequence":"additional","affiliation":[{"name":"Department of Hematology, Sultan Qaboos University, Muscat 123, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Pandita","sequence":"additional","affiliation":[{"name":"Kuwait Cancer Control Center, Shuwaikh 1031, Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6863-5748","authenticated-orcid":false,"given":"Salam","family":"Al-Kindi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Sultan Qaboos University, Muscat 123, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakir","family":"Bahzad","sequence":"additional","affiliation":[{"name":"Kuwait Cancer Control Center, Shuwaikh 1031, Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6618-4207","authenticated-orcid":false,"given":"Dayane","family":"Daou","sequence":"additional","affiliation":[{"name":"Gulf, Novartis Pharma Services AG, 4056 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Al Qudah","sequence":"additional","affiliation":[{"name":"Oncology, Gulf, Novartis Pharma Services AG, 4056 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/S0140-6736(21)01204-6","article-title":"Chronic myeloid leukaemia","volume":"398","author":"Cortes","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/GO.21.00194","article-title":"Magnitude and Temporal Trend of the Chronic Myeloid Leukemia: On the Basis of the Global Burden of Disease Study 2019","volume":"7","author":"Hu","year":"2021","journal-title":"JCO Glob. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life Expectancy of Patients with Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population","volume":"34","author":"Bower","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood.2021011722","article-title":"How I treat chronic-phase chronic myelogenous leukemia","volume":"139","author":"Berman","year":"2022","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs. bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"Mauro","year":"2021","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"801779","DOI":"10.3389\/fonc.2021.801779","article-title":"Potential Approaches versus Approved or Developing Chronic Myeloid Leukemia Therapy","volume":"11","author":"Andretta","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","article-title":"Chronic Myeloid Leukemia, Version 2. 2021, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Deininger","year":"2020","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-022-03446-1","article-title":"Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: Differences and similarities","volume":"117","year":"2023","journal-title":"Int. J. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2147\/JBM.S221317","article-title":"Myeloid Leukemias: A Glance at Middle Eastern Centers","volume":"10","author":"Khaled","year":"2019","journal-title":"J. Blood. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jiph.2019.12.006","article-title":"Evaluation and characterisation of Chronic myeloid leukemia and various treatments in Saudi Arabia: A retrospective study","volume":"13","author":"Algahtani","year":"2020","journal-title":"J. Infect. Public Health"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"882","DOI":"10.3109\/10428194.2014.935365","article-title":"Response to imatinib therapy in adult patients with chronic myeloid leukemia in Saudi population: A single-center study","volume":"56","author":"Alsobhi","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/j.htct.2022.02.002","article-title":"Hematologic malignancies of primary bone marrow involvement: A decade\u2019s experience in Bahrain","volume":"45","author":"Ismaeel","year":"2023","journal-title":"Hematol. Transfus Cell Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/bjh.16599","article-title":"TARGET: A survey of real-world management of chronic myeloid leukaemia across 33 countries","volume":"190","author":"Turkina","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/17474086.2022.2044779","article-title":"Patient characteristics and management practices in chronic myeloid leukemia in Turkey: Reflections from an expert meeting","volume":"15","author":"Ali","year":"2022","journal-title":"Expert Rev. Hematol."},{"key":"ref_16","unstructured":"Copland, M., Gibson, K., Milojkovic, D., Cross, N.C., Huntly, B., Billot, J., Ryan, J., and Mead, A. (2021, January 9\u201317). A survey of healthcare professionals in the United Kingdom to describe current pathways and management practices in chronic myeloid leukaemia: The ADAPT CML survey. Proceedings of the E-Poster (EP682) Presented at: 26th Congress of the European Hematology Association (Virtual), Frankfurt, Germany."},{"key":"ref_17","first-page":"5263","article-title":"Treatment Free Remission (TFR) in Chronic Myeloid Leukaemia (CML): The Tawam Hospital Experience","volume":"130","author":"Alam","year":"2017","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"12235","DOI":"10.1182\/blood-2022-164783","article-title":"Treatment Free Remission (TFR) in Chronic Myeloid Leukemia-Chronic Phase (CML-CP), Kuwait Experience","volume":"140","author":"Alhuraiji","year":"2022","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1182\/blood.2021012082","article-title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: A randomized, open-label phase 2 clinical trial","volume":"138","author":"Cortes","year":"2021","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood.2020006911","article-title":"How to manage CML patients with comorbidities","volume":"136","author":"Cortes","year":"2020","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"739171","DOI":"10.3389\/fonc.2021.739171","article-title":"Prognostic Factors for Overall Survival in Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network","volume":"11","author":"Specchia","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"80083","DOI":"10.18632\/oncotarget.11657","article-title":"Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: Effects on response rate, toxicity and outcome","volume":"7","author":"Iurlo","year":"2016","journal-title":"Oncotarget"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/11\/2114\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:52:03Z","timestamp":1760107923000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/11\/2114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,31]]},"references-count":22,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["cancers16112114"],"URL":"https:\/\/doi.org\/10.3390\/cancers16112114","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,31]]}}}